{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=24",
    "query": {
      "intervention": "Control Study Product",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 4231,
    "total_pages": 424,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T17:40:56.316Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02013050",
      "title": "A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "SGX942",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soligenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2013-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013050"
    },
    {
      "nct_id": "NCT02367846",
      "title": "Assessing the Impact of Contraceptives on Bone Health Using 41Ca",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Other Disorders of Bone Development and Growth"
      ],
      "interventions": [
        {
          "name": "Combined Oral Contraceptive (COC)",
          "type": "DRUG"
        },
        {
          "name": "Contraceptive Vaginal Ring (CVR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Penn State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 25 Years · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2015-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 1,
      "location_summary": "University Park, Pennsylvania",
      "locations": [
        {
          "city": "University Park",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02367846"
    },
    {
      "nct_id": "NCT01008527",
      "title": "Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "CP 870,893",
          "type": "DRUG"
        },
        {
          "name": "Peptides",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oncovir poly IC:LC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2009-10",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2015-09-24",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01008527"
    },
    {
      "nct_id": "NCT03018340",
      "title": "Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adjunctive Treatment of Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2016-12",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2019-11-14",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03018340"
    },
    {
      "nct_id": "NCT05016882",
      "title": "Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "NNC0194 0499 50 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo (NNC0194-0499)",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide 3 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide placebo",
          "type": "DRUG"
        },
        {
          "name": "NNC0174 0833 10 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "NNC0174 0833 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 698,
      "start_date": "2021-08-31",
      "completion_date": "2025-03-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 70,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05016882"
    },
    {
      "nct_id": "NCT07704359",
      "title": "Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Perianal Abscess",
        "Anal Fistula"
      ],
      "interventions": [
        {
          "name": "Amoxicillin + Clavulanate",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin + Metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2026-10-05",
      "completion_date": "2029-08-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07704359"
    },
    {
      "nct_id": "NCT01250496",
      "title": "Study With Aminophylline to Attenuate of the Side Effects of Regadenoson",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan"
      ],
      "interventions": [
        {
          "name": "Aminophylline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2010-11",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250496"
    },
    {
      "nct_id": "NCT04313088",
      "title": "Investigation of Eluxadoline for Diabetic Diarrhea",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Diarrhea",
        "Diabetes",
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Eluxadoline 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-07-01",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04313088"
    },
    {
      "nct_id": "NCT02218489",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "KPI-121",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2014-07",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218489"
    },
    {
      "nct_id": "NCT05198310",
      "title": "Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "KPL-404",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kiniksa Pharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 145,
      "start_date": "2021-12-14",
      "completion_date": "2024-05-06",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-10-21T17:40:56.316Z",
      "location_count": 19,
      "location_summary": "Apple Valley, California • Covina, California • Upland, California + 15 more",
      "locations": [
        {
          "city": "Apple Valley",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05198310"
    }
  ]
}